Collaborator:
Klinikum rechts der Isar, TU München, (TUM), Munich, Germany.
Studienleiter
Sebastian Zschaeck, MD Principal Investigator Charité
Kontakt
Sebastian Zschaeck, MD Kontakt: Phone: +4930450650764 E-Mail: sebastian.zschaeck@charite.de» Kontaktdaten anzeigen
Studienlocations (1 von 1)
Klinik für Radioonkologie und Strahlentherapie 13353 Berlin (Berlin) GermanyRekrutierend» Google-Maps Ansprechpartner: Sebastian Zschaeck, M.D.» Ansprechpartner anzeigen
1. Radiographic response to initial treatment (Time Frame - 3 months after study enrollment): radiographic response to treatment will be scored according to RECIST criteria and associated with the number of CTC
Secondary outcome:
1. Correlation between number of CTC isolated with HSP70 compared to EpCAM (Time Frame - 3 months (at both CTC assessment timepoints)): the number of CTCs obtained by the novel HSP70 method will be compared to the current gold standard that uses EpCAM. This will be performed for the whole cohort and separate for each tumor site
2. Correlation between differential expressed radiommic parameters between primary tumor and metastases and genetic alterations of the primary tumor and CTCs (Time Frame - 3 months (at both CTC assessment timepoints)): computed tomography parameters of primary tumors and metastases will be analysed and parameters extraced that are differentially expressed between both. The same will be performed for genomic mutations and gene expression of the primary tumor and CTC. Correlation analyses will be performed to analyze if radiographic parameters resemble genetic alterations
3. Progression free survival (Time Frame - 2 years): Progression free survival will be evaluated with the number of CTC as variable. This will be performed for the whole cohort and separate for each tumor site
4. Overall survival (Time Frame - 2 years): Overall survival will be evaluated with the number of CTC as variable. This will be performed for the whole cohort and separate for each tumor site
CTC isolation by HSP70: patients will receive additional blood examinations with quantification of circulating tumor cells by HSP70 antibodies and EpCAM.
Quelle: ClinicalTrials.gov
Sie können folgenden Inhalt einem Kollegen empfehlen:
"Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells"
Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.
Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!